The transforming growth factor beta-receptor I/activin receptor-like kinase 5 (TGFBR1/ALK5) and its close homologue ALK4 are receptor protein kinases associated with the development of diverse diseases, including cancer, fibrosis, heart diseases and dysfunctional immune response. Therefore, ALK4/5 are among the most studied kinases and several inhibitors have been developed. However, current commercially available inhibitors either lack selectivity or have not been comprehensively characterized, limiting their value for studying ALK4/5 function in cellular systems. To this end, we report the characterization of the 2-oxo-imidazopyridine, TP-008, a potent chemical probe with dual activity for ALK4 and ALK5 as well as the development of a matching negative control compound. TP-008 has excellent cellular potency and strongly abrogates phosphorylation of the substrate SMAD2 (mothers against decapentaplegic homolog 2). Thus, this chemical probe offers an excellent tool for mechanistic studies on the ALK4/5 signaling pathway and the contribution of these targets to disease.
Introduction
The transforming growth factor-β (TGF-β) superfamily of signaling ligands is a large family, which comprises in mammals at least 30 structurally related cytokines including the TGF-βs, bone morphogenetic proteins (BMPs), activins, growth and differentiation factors (GDFs), the proteins nodal and the anti-Muellerian hormone (AMH).(1) Because of its involvement in many cellular processes such as proliferation, cell growth, adhesion, migration, differentiation and other regulatory functions, the TGF-β signaling pathway has been widely studied. (1, 2) TGF-β signaling is initiated by the binding of a dimeric TGF-β ligand which assembles a heterotetrameric transmembrane serine-threonine kinase receptor complex, consisting of two TGF-β type II receptors (TGFBR2) and two type I receptors (TGFBR1/ALK5, also known as TβRI) (3) . Once this heterotetrameric complex is formed, ALK5 is activated and phosphorylates the intracellular regulatory SMADs (R-SMADs). R-SMADs in turn bind to the common SMAD (Co-SMAD) SMAD4, inducing their translocation into the nucleus, where they promote the expression of specific target genes ( Figure 1A) . Dysregulated expression of genes linked to this pathway has been associated with the development of cancer, fibrosis, immunity or heart diseases (4) (5) (6) (7) . Consequently, inhibition of TGF-β receptor superfamily has gained increasing attention over the last two decades, but so far no drug inhibiting TGF-β family receptors has been approved. Five type II and seven type I receptors, also termed activin-receptor like kinases (ALK1- 7) , have been identified in mammals, which have a similar sequence and domain structure composed of a ligand-binding extracellular domain, a transmembrane domain, and a cytoplasmic kinase domain (8) . They belong to the serine/threonine kinase receptor (STKR) subfamily, which is part of the tyrosine kinase-like (TKL) branch of kinases.
ALK5/TGFBR1 and ALK4/ACVR1B are both closely related and phosphorylate SMAD2 and SMAD3, whereas ALK1/2/3 and ALK6 phosphorylate SMAD1/5/8.
Several ALK4/5 inhibitors such as the clinical inhibitors Vactosertib (EW-7197; 1) and
Galunisertib (2), or the preclinical inhibitors, SD-208 (3) or GW-788388 (4) have been developed ( Figure. 1C ). Galunisertib is the most advanced ALK5 inhibitor which has now progressed to phase II clinical studies for treatment of different cancers (9, 10) . However, current inhibitors have insufficient selectivity for mechanistic studies, inhibiting five to ten additional kinases with significant activity. For instance, Vactosertib (1) also inhibits RIPK2 and VEGFR2 with IC50 values below 100 nM and Galunisertib (2) inhibits besides ALK4/5 RIPK2, TGFBR2, MINK, CSNK1A1, MAP4K4, GAK, CSNK1E1 and BMPR1B with IC50 values ranging from 190 nM to 470 nM (11, 12) . Recently Boehringer Ingelheim launched on the opnMe platform the compound BI-4659 to use as an ALK5 inhibitor. However also for this compound several off-targets have been described (13, 14) . Thus, there remains a pressing need to develop a more selective, potent and cell active ALK4/5 inhibitor. Analysis of the literature revealed that more than 50% of published studies in 2018, used ALK4/5 inhibitors, involved one of the compounds 1-4, whose selectivity profiles either reveal significant off targets (1-3) (11, 12) or lack comprehensive characterization (4) ( Figure 1C ). Therefore, a chemical probe for this key target and important signaling molecule is of high interest for the research community. We and others have defined stringent criteria for chemical probes. A suitable tool compound for protein kinase research should display a biochemical potency below 100 nM at KM of ATP, a cellular potency below 1 µM and a selectivity profile with no other off-targets within 30-fold apart potency from closely related paralogues (15, 16) . Ideally, the chemical probe is also accompanied by a negative control compound, which is structurally related, but inactive against the target of interest. To increase the availability of chemical probes, the Structural Genomics Consortium (SGC) and its partners established the Donated Chemical Probe program through which high-quality compounds from the pharmaceutical industry or academic research laboratories are donated to the scientific community, sometimes following additional characterization and development of a suitable control compound (17) . Recently, a series of inhibitors including compound TP-008 (5) was reported by Takeda as a potent ALK5 inhibitor with an IC50 value of 25 nM and a promising pharmacokinetic profile (18) . TP-008 (5) shows no CYP inhibition (CYP1A2, CYP3A4), a low clearance and a low hERG liability (21% inhibition @ 10 µM). Initial selectivity profiling at 1 µM in a panel of about 50 kinases showed favorable selectivity and revealed no significant off-targets (18) . Here, we report the comprehensive characterization of TP-008 as a chemical probe for ALK4/5 and the development of a suitable negative control.
Results and Discussion
In order to assess the selectivity of compound 5 (TP-008) in a wider kinase assay panel, TP-008 was screened in the scanMax SM Kinase Assay Panel by Eurofins (DiscoverX) against 469 kinases (19, 20) . No off-target activity was observed for TP-008 (5) at a screening concentration of 1 µM, while ALK4 and ALK5 exhibited 3.3% and 3.6% residual binding of the tracer molecule in this displacement assay format, confirming that TP-008 is a highly selective dual ALK4/5 inhibitor ( Figure 3A , Table S5 ). Next, we tested the activity of TP-008 against both kinases in an enzyme kinetic kinase assay to determine the in vitro potency on ALK4 and ALK5 (21) . In comparison, Vactosertib (1) and GW-788388 (4) were also investigated. All assays were performed at an ATP concentration of 1 µM. Interestingly, TP-008 showed similar activity on both kinases with comparable IC50 values of 113 nM against ALK4 and 343 nM against ALK5, respectively, ( Figure 2A ) in good agreement with the results from the scanMax SM Kinase Assay ( Figure 3 ). In comparison, GW-788388 and Vactosertib showed IC50 values against ALK4/5 in the same assay of 155/222 nM and 8.3/11.8 nM, respectively (Table S1, Figure S1 and S2).
Sequence alignment of ALK4 and ALK5 demonstrated a sequence identity of ~70% and an identity of greater than 90% in the ATP-binding pocket (Tables S2-S4 ). The glycine rich loop, αC, β4, β5, hinge-region and αD especially were noted to share identical amino acid residues, indicating that selectivity between these two kinases may be difficult to achieve, if not impossible for an ATP competitive kinase inhibitor (type I or II). In contrast, one of the major differences of the type I receptors (ALK1-3 and ALK6) over ALK4/5 is the somewhat bulkier gatekeeper (threonine vs. serine), which has been explored to achieve selectivity between ALK subfamilies. However, the closest member to ALK4/5, within the type I receptors, is ALK7, which also harbors a serine gatekeeper and differs just in one position in the hinge region (D281 in ALK5 vs. E271 in ALK7), the αD-Helix (F289 vs. Y279) and the intervening linker motif (H285 vs. Q275). Serine gatekeeper residues are uniquely found in ALK4/5/7 offering a strategy for the design of kinome wide selectivity.
Next, we performed molecular docking studies with TP-008 (5) using the ALK5 structure (PDB-ID: 3HMM (22) ) in order to understand the possible binding mode and as a basis for the design of a related negative control. In all binding modes generated, the pyridine nitrogen of TP-008 (5) mediated the interaction with the hinge region ( Figure 2B ). Therefore, two closely related derivatives were designed and synthesized, either without the nitrogen or with an additional methyl group to block the interaction with the hinge region ( Figure 2C ). Synthesis of these compounds was performed in four-steps, starting with the building block 2-(5-chloro-2fluorophenyl)-5-methylpyridin-4-amine (6) . 6 was coupled to either 1-bromo-2-nitrobenzene (7) or 1-bromo-4-methyl-2-nitrobenzene (8) in a Buchwald-Hartwig amination to provide the diarylamines 9 and 10. The nitro group in 9 and 10 was reduced to the primary amines 11 and 12. The ring closure of 11 and 12 using CDI afforded the benzimidazolones derivatives 13 and 14, which were finally coupled to 2-bromoacetamide resulting in two potential negative control compounds 15 (THAI11) and 16 (THAI14). Both compounds were also screened in the scanMax SM Kinase Assay Panel by Eurofins (DiscoverX) ( Figure 3 ). For 15, no significant hits were observed at 1 µM, whereas for 16 NEK5 appeared as an off-target, which was likely to be a false positive hit (s. TableS7). However, we thus chose 15 as negative control compound for TP-008 (5) .
We next used a cellular NanoBRET TM assay to evaluate the cellular selectivity of compounds 5 (TP-008), 15 (THAI11) and 16 (THAI14) against the closest off-targets of 5 suggested by the in vitro kinase assay for compound 5 (namely MAPK9, JAK1, PIK3CA, PNCK, DDR1; Figure. 3B) (23) . This assay employs the full length protein kinases fused to a luciferase (NLuc) and is performed in live HEK293T cells under physiological ATP concentrations. We recently showed that it provides the advantage of determining differing inhibition profiles comparing the cellular context to in vitro assays (23) . All compounds tested in the NanoBRET TM assay had an IC50 higher than 20 µM for the suggested off-target kinases ( Figure 3C ), indicating that the activity of 5, 15 and 16 was negligent against these kinases in cells at concentrations relevant to ALK4/5 inhibition.
We assessed the cellular potency of compounds 5, 15 and 16 against their target receptor signaling pathways, employing a SMAD2/3-responsive luciferase-based transcriptional reporter assay, in HEK293 cells stimulated with either TGF-β for ALK5 or activin A for ALK4, respectively. Vactosertib (1) and GW788388 (4) were tested in parallel for reference ( Figure   4A , S3). All three compounds displayed dose-dependent inhibition of the reporter in agreement with their activities in enzyme catalytic assays ( Figure 4A, S3 ). Compound 5 yielded IC50values of 245 nM and 526 nM against ALK5 and ALK4, respectively, while Vactosertib was more potent with IC50-values 24 and 12 nM against ALK5 and ALK4. GW788388 exhibited some selectivity for ALK4 with an IC50 of 44 nM compared to 454 nM against ALK5. Pleasingly, both negative control compounds 15 and 16, were inactive up to a compound concentration of 10 µM, validating the in silico-based design. In addition to the reporter assay, immunoblotting was performed to study the direct effect of the compounds on phosphorylation of the downstream targets SMAD2/3 in C2C12 cells ( Figure 4B ). TP-008 (5), Vactosertib (1) and GW788388 (4) inhibited the phosphorylation of SMAD2/3 at 1 µM, whereas Vactosertib (1) was already active at 100 nM, which is in good agreement with the promoter gene assay. As expected, the two negative control compounds 15 (THAI11) and 16 (THAI14) did not inhibit phosphorylation of SMAD2/3 at concentrations up to 10 µM.
In summary, in this short report we have comprehensively characterized a chemical probe, TP-008, for ALK4/5 and designed two highly related negative control compounds based on a docking model. Many potent ALK5 inhibitors have been published, but their utility for cell signaling studies has been limited by their lack of selectivity. With TP-008, we present a dual inhibitor of ALK4/5 with good cellular potency and the best selectivity profile of available inhibitors so far. Molecular docking indicates that selectivity is driven by the 2-fluoro-5chlorophenyl moiety, which penetrates deep into the hydrophobic back pocket to pack between the α-C helix residues Tyr49 and Glu45. In addition, ALK4/5 possess a smaller serine residue as the gatekeeper, which is rare within the human kinome. The generated negative control compounds were inactive in the complete KINOMEscan® as well as in the cellular assays.
However, we would like to emphasize that the closest paralog of ALK4/5, which is ALK7 as described above in the sequence alignment, was neither part of the scanMAX SM Panel by Eurofins/DiscoverX, nor a functional assay that is commercial available by Reaction Biology. Therefore, we cannot exclude activity of TP-008 on this kinase. To conclude, with TP-008 and THAI11, which we henceforth rename as TP-008n, we can present a chemical probe package consisting of a positive and negative control compounds that display the best selectivity of all known ALK5 inhibitors. Importantly, the probe compound TP-008 was able to inhibit the phosphorylation of downstream substrates, whereas TP-008n showed no effect. We recommend using both compounds at a concentration of 1 µM to study the effects of inhibiting ALK5 and ALK4 in cells. Western blot analysis. 500,000 C2C12 cells in 2 mL of culture medium were seeded into each well of 6-well plates (Corning) and incubated overnight in a humidified, 37 °C incubator with 5% carbon dioxide to allow cell attachment. Cells were serum-starved for 1 hour in 2 mL of Opti-MEM (Gibco). Cells were subsequently incubated with ligand and test compounds (1; NanoBRET Tm target engagement assays. The assay was performed as described previously (23) . In brief: Full-length kinase ORF (Promega) cloned in frame with a NanoLuc-vector (as indicated in Table S8 ) was transfected into HEK293T cells using FuGENE HD (Promega, E2312) and proteins were allowed to express for 20 h. Serially diluted inhibitor and NanoBRET TM Kinase Tracer (as indicated in Table S8 ) were pipetted into white 384-well plates (Greiner 781 207) using an ECHO 555 acoustic dispenser (Labcyte). The corresponding transfected cells were added and reseeded at a density of 2 x 105 cells/mL after trypsinization and resuspension in Opti-MEM without phenol red (Life Technologies). The system was allowed to equilibrate for 2 hours at 37 °C and 5 % CO2 prior to BRET measurements. To measure BRET, NanoBRET TM NanoGlo Substrate + Extracellular NanoLuc Inhibitor (Promega, N2160) were added as per the manufacturer's protocol, and filtered luminescence was measured on a PHERAstar plate reader (BMG Labtech) equipped with a luminescence filter pair (450 nm BP filter (donor) and 610 nm LP filter (acceptor)). Competitive displacement data were then plotted using GraphPad Prism 8 software using a 4-parameter curve fit with the following equation: Y=Bottom + (Top-Bottom) / (1+10^((LogIC50-X)*HillSlope)) Docking-Study. Molecular docking studies on ALK5 were performed with the platform seeSAR v8.1 (24) . The crystal structure 3HHM was selected due to similar structural features between the co-crystallized ligand and TP-008. The binding site was defined using the cocrystallized ligand as the center point for selecting amino acids in the radius of 6.5 Å. Redocking of the co-crystallized ligand showed similar binding pose as the reference, presenting the same interactions with the hinge region and Lys 32 of ALK5. Following this analysis, TP-008 was docked and 10 poses were generated. All 10 poses showed very similar binding modes, with the pyridine moiety interacting with the hinge region, while the main differences observed were from the flexibility of the amide moiety, with possible interactions with the backbone of residues Ile11 and Ser87 and hydrogen bond with residue Asp90.
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